Evropska unija - slovenščina - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer d.o.o. - ciproteronacetat - tableta - ciproteronacetat 100 mg / 1 tableta - ciproteron

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer d.o.o. - ciproteronacetat - tableta - ciproteronacetat 50 mg / 1 tableta - ciproteron

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer d.o.o. - etinilestradiol; ciproteronacetat - obložena tableta - etinilestradiol 0,035 mg / 1 tableta  ciproteronacetat2 mg / 1 tableta; ciproteronacetat 2 mg / 1 tableta - ciproteron in estrogen

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - etinilestradiol; ciproteronacetat - obložena tableta - etinilestradiol 0,035 mg / 1 tableta  ciproteronacetat2 mg / 1 tableta; ciproteronacetat 2 mg / 1 tableta - ciproteron in estrogen

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - etinilestradiol; ciproteronacetat - obložena tableta - etinilestradiol 0,035 mg / 1 tableta  ciproteronacetat2 mg / 1 tableta; ciproteronacetat 2 mg / 1 tableta - ciproteron in estrogen

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer pharma ag - estradiolvalerat; ciproteronacetat - obložena tableta - estradiolvalerat 2 mg / 1 tableta  ciproteronacetat1 mg / 1 tableta; ciproteronacetat 1 mg / 1 tableta - ciproteron in estrogen

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplazem, kastracija-odporne - antineoplastična sredstva - treatment of adult patients with prostate cancer.